I think it's getting close to action stations for our much maligned stock after hearing Martin Rogers and Michael Johnson are targeting select biotech friendly broking firms around the country.
This option entitlement issue and the re-con have set the scene for the company to hit the ground running again.
I have no doubt the new team will re-rate our stock after getting a call from a broker who was big in ISN telling me CGP was now on his radar.
Early warning folks.........don't say you weren't told LOL!!!!
Please DYOR
Ant
CGP Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held